Lineage Cell Therapeutics price target raised to $4 from $3 at B. Riley

B. Riley raised the firm’s price target on Lineage Cell Therapeutics (LCTX) to $4 from $3 and keeps a Buy rating on the shares. Lineage Cell Therapeutics highlighted COR1, a wholly-owned corneal endothelial cell therapy targeting Fuchs Endothelial Corneal Dystrophy and Bullous Keratopathy, leveraging its AlloSCOPE platform that underpins the Roche-partnered OpRegen, the analyst tells investors in a research note. The company’s differentiated manufacturing approach could yield a scalable, cost-effective, wholly-owned product addressing 2M-6M U.S. patients, complementing ongoing OpRegen and peer gene therapy developments, the firm says.